Morimoto S, Nishimura J, Miyauchi A, Takai S, Okada Y, Onishi T, Fukuo K, Lee S, Kumahara Y
J Clin Endocrinol Metab. 1982 Sep;55(3):594-6. doi: 10.1210/jcem-55-3-594.
Calcitonin (CT) was measured by RIA in samples of plasma and cerebrospinal fluid (CSF) obtained simultaneously from 27 normal volunteers and 8 patients with medullary thyroid carcinoma to examine the extent of penetration of CT across the blood-brain barrier. CT concentrations in plasma and CSF were 68.2 +/- 25.1 pg/ml (mean +/- SD; range, less than 25-110) and 38.5 +/- 12.1 pg/ml (range, less than 25-56), respectively, in normal subjects and 5,650 +/- 4,120 pg/ml (range, 980-21,100) and 36.1 +/- 11.1 pg/ml (range, less than 25-45), respectively, in patients with medullary thyroid carcinoma. No significant difference was observed in the mean concentrations of CT in CSF from normal subjects and that from patients with medullary thyroid carcinoma. The concentration of CT in CSF from patients with medullary thyroid carcinoma was only 0.05-2.5% the concentration of CT in plasma. Moreover, there was no significant correlation between the concentrations of CT in plasma and CSF from normal subjects, from patients with medullary thyroid carcinoma, or when normal and patient groups were combined. It is concluded that penetration of CT from blood in CSF is minimal.
通过放射免疫分析法(RIA)测定了27名正常志愿者和8例甲状腺髓样癌患者同时采集的血浆和脑脊液(CSF)样本中的降钙素(CT),以检测CT穿越血脑屏障的程度。正常受试者血浆和脑脊液中的CT浓度分别为68.2±25.1 pg/ml(平均值±标准差;范围,小于25 - 110)和38.5±12.1 pg/ml(范围,小于25 - 56),甲状腺髓样癌患者的分别为5650±4120 pg/ml(范围,980 - 21100)和36.1±11.1 pg/ml(范围,小于25 - 45)。正常受试者和甲状腺髓样癌患者脑脊液中CT的平均浓度未观察到显著差异。甲状腺髓样癌患者脑脊液中CT的浓度仅为血浆中CT浓度的0.05% - 2.5%。此外,正常受试者、甲状腺髓样癌患者或正常与患者组合并时,血浆和脑脊液中CT的浓度之间均无显著相关性。结论是CT从血液进入脑脊液的渗透极少。